Decrease in growth hormone and insulin-like growth factor (IGF) - 1 Release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus in a patient with acromegaly

Croatian Medical Journal

Volumn 48, Issue 1, 2007, Pages 87-91

  Gradišer, Marina ^a   Matovinović, Martina ^a   Vrkljan, Milan ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; ROSIGLITAZONE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROATIA; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HISTOLOGY; HORMONE RELEASE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS MACROADENOMA; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; TRANSSPHENOIDAL SURGERY;

ACROMEGALY; ADENOMA; ADULT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; THIAZOLIDINEDIONES;

EID: 33847215098     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Katznelson L. Diagnosis and treatment of acromegaly. Growth Horm IGF Res. 2005;15 Suppl A:S31-5.
2. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho KJ, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-9.
3. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-26.
4. Frohman LA. Acromegaly: what constitutes optimal therapy? J Clin Endocrinol Metab. 1996;81:443-5.
5. Wass JA, Shalet SM, editors. Oxford textbook of endocrinology. 1st ed. Oxford: Oxford University Press; 2002.
6. Katznelson L, Kleinberg D, Vance ML, Stavrou S, Pulaski KJ, Schoenfeld DA, et al. Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. Clin Endocrinol (Oxf). 2001;54:183-8.
7. Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, et al. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. Eur J Endocrinol. 2000;143:615-21.
8. Turner HE. Clinical features, investigation and complications of acromegaly. In: Wass JA, editor. Handbook of acromegaly. Bristol (UK): Bio Scientifica Ltd.; 2001. p. 24-5.
9. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-9.
10. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004;21:415-22.
11. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47:507-14.
12. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-6.
13. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem. 1999;274:9116-21.
14. Heaney AP, Fernando M, Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 2003;111:1381-8.
15. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004;150:863-75.
16. Heaney AP. Novel pituitary ligands: peroxisome proliferator activating receptor-gamma. Pituitary. 2003;6:153-9.
17. Hull SS, Sheridan B, Atkinson AB. Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf). 2005;62:259-61.
18. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M, et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med. 2004;21:415-22.